-  INCLUSION CRITERIA:

          -  Patients must have histologically confirmed locally recurrent adenocarcinoma of the
             prostate after prior radiation (EBRT or brachytherapy).

          -  PSA failure after definitive radiation as defined by the Phoenix criteria (PSA
             elevation at least 2 ng/dL above post-radiotherapy nadir)

          -  Age greater than or equal to 18 years.

          -  ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to
             60%).

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document.

        EXCLUSION CRITERIA:

          -  Patients who are receiving any other investigational agents.

          -  PSA greater than or equal to 20 ng/dL if no prior DCFPyL scan obtained (If PSA > 20
             and DCFPyL obtained within 3 months prior to enrollment shows no evidence of
             metastatic disease, subjects may be included in the study)

          -  Biochemical recurrence within one year of completion of radiotherapy

          -  Need for chronic anticoagulation therapy (chronic low dose aspirin is not an
             exclusion)

          -  Pre-existing and ongoing radiation-related grade 3 bowel or bladder toxicity

          -  Inflammatory bowel disease

          -  Active Lupus or Active scleroderma

          -  Patients with distant metastatic disease (prostate adjacent adenopathy is not an
             exclusion)

          -  Prior prostatectomy

          -  Subjects with any coexisting medical or psychiatric condition that is likely to
             interfere with study procedures and/or results.

          -  Subjects with severe claustrophobia that is unresponsive to oral anxiolytics

          -  Other medical conditions deemed by the Principal Investigator (or associates) to make
             the subject unsafe or ineligible for protocol procedures

          -  Subjects weighing > 350 lbs. (weight limit for scanner table), or unable to fit within
             the imaging gantry

          -  Serum creatinine > 2 times the upper limit of normal

          -  Total bilirubin > 2 times the upper limit of normal OR in patients with Gilbert s
             syndrome, a total bilirubin > 3.0.

          -  Liver transaminases (ALT, AST) greater than 3 times the upper limit of normal

          -  Patients with positive Human Immunodeficiency Virus (HIV) status and currently
             requiring treatment with agents known to sensitize to irradiation, such as protease
             inhibitors, will be excluded